罪犯斑块形态决定ACS炎症风险与临床结局
前瞻性转化研究纳入398例ACS患者,62%为斑块破裂(RFC-ACS),25%为完整纤维帽侵蚀(IFC-ACS)。IFC-ACS患者2年MACE+发生率低于RFC-ACS(14.3% vs 26.7%,P=0.02),且炎症蛋白组表达更低,白介素-1β水平在3个月内下降。
要点
- IFC-ACS患者2年MACE+风险显著低于RFC-ACS(14.3% vs 26.7%,P=0.02)。
- IFC-ACS炎症蛋白组表达更低,白介素-1β水平3个月内下降(P<0.001)。
- RFC-ACS无MACE+者白介素-6下降(P=0.01),有MACE+者持续高。
核心结论
- IFC-ACS后炎症反应 distinct 且MACE+风险更低,为个体化抗炎治疗提供假设生成数据。
研究设计与样本
- 前瞻性转化OPTICO-ACS研究项目分析,纳入398例连续ACS患者。
主要发现
- IFC-ACS患者2年MACE+发生率14.3%,RFC-ACS为26.7%(P=0.02)。
- IFC-ACS患者炎症蛋白组表达更低,包括白介素-6及白介素-1β反应相关蛋白。
- IFC-ACS患者血浆白介素-1β从基线至3个月下降(P<0.001),RFC-ACS保持稳定(P=0.25)。
- RFC-ACS无MACE+者白介素-6下降(P=0.01),有MACE+者持续高。
关键数值与推荐
- IFC-ACS与RFC-ACS的MACE+比较:14.3% vs 26.7%,P=0.02。
- IFC-ACS白介素-1β基线至3个月下降P<0.001;RFC-ACS稳定P=0.25。
- RFC-ACS无MACE+者白介素-6下降P=0.01。
临床怎么用
- 识别ACS罪犯斑块形态(RFC vs IFC)可能有助于区分炎症风险并指导抗炎治疗分配。
局限性
- 研究为假设生成性,抗炎治疗个体化分配策略尚需未来临床试验评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Rupture of the fibrous cap (RFC) and erosion of an intact fibrous cap (IFC) are the two predominant mechanisms causing acute coronary syndromes (ACS). It is uncertain whether clinical outcomes are different following RFC-ACS vs. IFC-ACS and whether this is affected by a specific inflammatory response. The prospective, translational OPTIcal-COherence Tomography in Acute Coronary Syndrome study programme investigates the impact of the culprit lesion phenotype on inflammatory profiles and prognosis in ACS patients. METHODS AND RESULTS: This analysis included 398 consecutive ACS patients, of which 62% had RFC-ACS and 25% had IFC-ACS. The primary endpoint was a composite of cardiac death, recurrent ACS, hospitalization for unstable angina, and target vessel revascularization at 2 years [major adverse cardiovascular events (MACE+)]. Inflammatory profiling was performed at baseline and after 90 days. Patients with IFC-ACS had lower rates of MACE+ than those with RFC-ACS (14.3% vs. 26.7%, P = 0.02). In 368-plex proteomic analyses, patients with IFC-ACS showed lower inflammatory proteome expression compared with those with RFC-ACS, including interleukin-6 and proteins associated with the response to interleukin-1β. Circulating plasma levels of interleukin-1β decreased from baseline to 3 months following IFC-ACS (P < 0.001) but remained stable following RFC-ACS (P = 0.25). Interleukin-6 levels decreased in patients with RFC-ACS free of MACE+ (P = 0.01) but persisted high in those with MACE+. CONCLUSION: This study demonstrates a distinct inflammatory response and a lower risk of MACE+ following IFC-ACS. These findings advance our understanding of inflammatory cascades associated with different mechanisms of plaque disruption and provide hypothesis generating data for personalized anti-inflammatory therapeutic allocation to ACS patients, a strategy that merits evaluation in future clinical trials.
引用
- Gerhardt, Seppelt, Abdelwahed, et al. Culprit plaque morphology determines inflammatory risk and clinical outcomes in acute coronary syndrome. Eur Heart J. 2023. PMID: 37381774. doi:10.1093/eurheartj/ehad334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。